News

Public · Published

Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences reported positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial met both primary endpoints: reduced neuroinflammation at the 50-microgram dose versus placebo after 12 weeks, and safety and tolerability at both tested doses.

Published:

Updated:

What happened

Tiziana Life Sciences reported positive topline results from its Phase 2a INFORM-MS trial of intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial met both primary endpoints: reduced neuroinflammation at the 50-microgram dose versus placebo after 12 weeks, and safety and tolerability at both tested doses.

Confirmed

Global impact / market context

The findings offer early evidence that foralumab may address inflammation and fatigue in a form of multiple sclerosis with no specifically FDA-approved treatment, potentially supporting further development. However, a small, early-stage trial does not establish lasting benefit or show that regulators will approve the treatment.

Analyst inference

For Tiziana, positive trial findings could improve the case for spending on the next development stage and attract investor interest, while disappointing follow-up evidence could weaken that case. The supplied report gives no trial size, financial details, or share-price response to assess commercial impact.

Analyst inference

What to watch

  1. Watch for fuller trial results, including participant numbers and detailed fatigue findings; the article reports average fatigue-score improvement but gives no comparison with placebo. Analyst inference
  2. Further studies and regulatory review would be needed before any treatment could be marketed; the article does not state a development timetable or approval plan. Analyst inference
  3. Track whether later evidence confirms reduced neuroinflammation and acceptable safety at both doses, since the reported primary endpoint comparison was for the 50-microgram dose versus placebo. Analyst inference

Evidence